BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 28830083)

  • 1. Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension.
    Juraschek SP; Appel LJ; Miller ER
    Am J Hypertens; 2017 Sep; 30(9):871-875. PubMed ID: 28830083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
    Wright JT; Bakris G; Greene T; Agodoa LY; Appel LJ; Charleston J; Cheek D; Douglas-Baltimore JG; Gassman J; Glassock R; Hebert L; Jamerson K; Lewis J; Phillips RA; Toto RD; Middleton JP; Rostand SG;
    JAMA; 2002 Nov; 288(19):2421-31. PubMed ID: 12435255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
    Agodoa LY; Appel L; Bakris GL; Beck G; Bourgoignie J; Briggs JP; Charleston J; Cheek D; Cleveland W; Douglas JG; Douglas M; Dowie D; Faulkner M; Gabriel A; Gassman J; Greene T; Hall Y; Hebert L; Hiremath L; Jamerson K; Johnson CJ; Kopple J; Kusek J; Lash J; Lea J; Lewis JB; Lipkowitz M; Massry S; Middleton J; Miller ER; Norris K; O'Connor D; Ojo A; Phillips RA; Pogue V; Rahman M; Randall OS; Rostand S; Schulman G; Smith W; Thornley-Brown D; Tisher CC; Toto RD; Wright JT; Xu S;
    JAMA; 2001 Jun; 285(21):2719-28. PubMed ID: 11386927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertension Treatment Effects on Orthostatic Hypotension and Its Relationship With Cardiovascular Disease.
    Juraschek SP; Appel LJ; Miller ER; Mukamal KJ; Lipsitz LA
    Hypertension; 2018 Oct; 72(4):986-993. PubMed ID: 30354704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
    Becker MA; Schumacher HR; Espinoza LR; Wells AF; MacDonald P; Lloyd E; Lademacher C
    Arthritis Res Ther; 2010; 12(2):R63. PubMed ID: 20370912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of hyperuricemia and serum uric acid lowering therapy with mortality in hemodialysis patients.
    Rohn B; Jansing W; Seibert FS; Pfab T; Cinkilic O; Paßfall J; Schmidt S; Babel N; Bauer F; Westhoff TH
    Ren Fail; 2020 Nov; 42(1):1067-1075. PubMed ID: 33076736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to target uric acid to retard CKD progression.
    Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
    Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan.
    Koto R; Nakajima A; Horiuchi H; Yamanaka H
    Ann Rheum Dis; 2021 Nov; 80(11):1483-1490. PubMed ID: 34158371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia.
    Levy GD; Rashid N; Niu F; Cheetham TC
    J Rheumatol; 2014 May; 41(5):955-62. PubMed ID: 24692523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
    Juraschek SP; Kovell LC; Miller ER; Gelber AC
    Arthritis Care Res (Hoboken); 2015 Apr; 67(4):588-92. PubMed ID: 25201123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
    Jackson RL; Hunt B; MacDonald PA
    BMC Geriatr; 2012 Mar; 12():11. PubMed ID: 22436129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
    Levy G; Shi JM; Cheetham TC; Rashid N
    Perm J; 2018; 22():17-142. PubMed ID: 30201087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with gout differ from healthy subjects in renal response to changes in serum uric acid.
    Liu S; Perez-Ruiz F; Miner JN
    Joint Bone Spine; 2017 Mar; 84(2):183-188. PubMed ID: 27324603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.
    Thornley-Brown D; Wang X; Wright JT; Randall OS; Miller ER; Lash JP; Gassman J; Contreras G; Appel LJ; Agodoa LY; Cheek D
    Arch Intern Med; 2006 Apr; 166(7):797-805. PubMed ID: 16606818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achievement of Target Serum Uric Acid Levels and Factors Associated with Therapeutic Failure among Japanese Men Treated for Hyperuricemia/Gout.
    Katayama A; Yokokawa H; Fukuda H; Ono Y; Isonuma H; Hisaoka T; Naito T
    Intern Med; 2019 May; 58(9):1225-1231. PubMed ID: 30626825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.
    Norris K; Bourgoigne J; Gassman J; Hebert L; Middleton J; Phillips RA; Randall O; Rostand S; Sherer S; Toto RD; Wright JT; Wang X; Greene T; Appel LJ; Lewis J;
    Am J Kidney Dis; 2006 Nov; 48(5):739-51. PubMed ID: 17059993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout.
    Steinberg AS; Vince BD; Choi YJ; Martin RL; McWherter CA; Boudes PF
    J Rheumatol; 2017 Mar; 44(3):374-379. PubMed ID: 27980008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.